TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.00 (+2.24%)
Close on Nov 20, 2026Market cap $9.89MP/E –Yield –
TScan Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
TScan Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$118.44M. For fiscal 2025 it was -$139.73M. The highest annual figure on record is -$7.26M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$139.73M | – |
| FY2024 | Dec 31, 2024 | -$114.65M | – |
| FY2023 | Dec 31, 2023 | -$64.50M | – |
| FY2022 | Dec 31, 2022 | -$70.73M | – |
| FY2021 | Dec 31, 2021 | -$58.62M | – |
| FY2020 | Dec 31, 2020 | -$7.26M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.55M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.29M | -543.9% |
| Q2 FY2024 | Jun 30, 2024 | -$27.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.24M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.44M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.43M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.66M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.49M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.13M | – |
See a number that looks wrong?